1.31
+3.97%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Innate Pharma
Its shares trade on Euronext Paris under the ticker IPH.PA. It has been listed since 31 October 2006. In the fiscal year to 31 December 2025, it reported revenue of €2.8m and a net loss of €49.2m. At that date it held total assets of €62.7m and shareholders' equity of −€21.7m.
Innate Pharma SA is a biopharmaceutical company. The company is headquartered in Marseille, Paca. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The firm works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 31 Oct 2006
- Employees
- 235
- Website
- innate-pharma.com ↗
Leadership
Pay as last reported
- Dr. Irina Staatz-GranzerChairwoman of the Board of Directors, since 2009€100,000
- Mr. Jonathan DickinsonChief Executive Officer, Member of the Leadership Team€435,249
- Ms. Pascale BoisselIndependent Vice Chairwoman of the Supervisory Board, since 2020€64,000
- Mr. Frederic LombardChief Financial Officer, Member of the Leadership Team
- Mr. Yannis MorelChief Operating Officer, Executive Vice President, Member of the Executive Board, Member of the Leadership Team€709,792
- Dr. Sonia QuaratinoExecutive Vice President, Member of the Executive Board, Chief Medical Officer, Member of the Leadership Team€770,500
- Prof. Eric VivierSenior Vice President, Chief Scientific Officer, Member of the Leadership Team
- Ms. Odile LaurentVice President - Human Resources, Member of the Leadership Team
- Mr. Henry WheelerVice President - Investor Relations and Communications, Member of the Leadership Team
- Ms. Claire de Saint-BlanquatVice President - Legal and Corporate Affairs, Secretary of the Supervisory Board, Member of the Leadership Team
- Dr. Nicolas BeltraminelliVice President, Chief Development Officer, Member of the Leadership Team
- Ms. Odile BelzunceVice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 53
- Environment
- 58
- Social
- 49
- Governance
- 51
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong portfolio of innovative drug candidates.
- Collaborative partnerships with renowned pharmaceutical companies.
- Expertise in immuno-oncology, a rapidly growing field.
- Solid financial position and resources for research and development.
Weaknesses
- Limited commercialized products and dependence on partnerships.
- Reliance on successful clinical trials for revenue generation.
- Vulnerability to changes in regulations or intellectual property rights.
- Lack of global market presence compared to larger pharmaceutical companies.
Opportunities
- Rising demand for immunotherapies and targeted treatment options.
- Potential for expansion into emerging markets with unmet medical needs.
- Possibility of strategic partnerships for further drug development.
- Increasing focus on personalized medicine and precision therapies.
Threats
- Intense competition in the immuno-oncology sector.
- Regulatory hurdles and approval challenges for new drugs.
- Pricing pressures and reimbursement uncertainties.
- Potential for disruptive technologies to replace current treatment approaches.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.